Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
19
pubmed:dateCreated
2002-9-5
pubmed:abstractText
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives were synthesized and characterized as activators of adenosine 5'-triphosphate (ATP) sensitive potassium (K(ATP)) channels in the beta-cells by measuring effects on membrane potential and insulin release in vitro. The effects on vascular tissue in vitro were measured on rat aorta and small mesenteric vessels. Selected compounds were characterized as competitive inhibitors of [(3)H]glibenclamide binding to membranes of HEK293 cells expressing human SUR1/Kir6.2 and as potent inhibitors of insulin release in isolated rat islets. 6-Chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (54) was found to bind and activate the SUR1/Kir6.2 K(ATP) channels in the low nanomolar range and to be at least 1000 times more potent than the reference compound diazoxide with respect to inhibition of insulin release from rat islets. Several compounds, e.g., 3-propylamino- (30), 3-isopropylamino- (34), 3-(S)-sec-butylamino- (37), and 3-(1-methylcyclopropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (53), which were found to be potent and beta-cell selective activators of K(ATP) channels in vitro, were found to inhibit insulin secretion in rats with minimal effects on blood pressure and to exhibit good oral pharmacokinetic properties.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0022-2623
pubmed:author
pubmed:issnType
Print
pubmed:day
12
pubmed:volume
45
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4171-87
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:12213059-ATP-Binding Cassette Transporters, pubmed-meshheading:12213059-Adenosine Triphosphate, pubmed-meshheading:12213059-Animals, pubmed-meshheading:12213059-Binding, Competitive, pubmed-meshheading:12213059-Biological Availability, pubmed-meshheading:12213059-Blood Pressure, pubmed-meshheading:12213059-Body Temperature, pubmed-meshheading:12213059-Cell Line, pubmed-meshheading:12213059-Female, pubmed-meshheading:12213059-Glucose, pubmed-meshheading:12213059-Heart Rate, pubmed-meshheading:12213059-Humans, pubmed-meshheading:12213059-Insulin, pubmed-meshheading:12213059-Islets of Langerhans, pubmed-meshheading:12213059-Male, pubmed-meshheading:12213059-Membrane Potentials, pubmed-meshheading:12213059-Mice, pubmed-meshheading:12213059-Muscle, Smooth, pubmed-meshheading:12213059-Muscle Contraction, pubmed-meshheading:12213059-Potassium Channels, pubmed-meshheading:12213059-Potassium Channels, Inwardly Rectifying, pubmed-meshheading:12213059-Rats, pubmed-meshheading:12213059-Rats, Sprague-Dawley, pubmed-meshheading:12213059-Rats, Wistar, pubmed-meshheading:12213059-Receptors, Drug, pubmed-meshheading:12213059-Stereoisomerism, pubmed-meshheading:12213059-Structure-Activity Relationship, pubmed-meshheading:12213059-Thiadiazines
pubmed:year
2002
pubmed:articleTitle
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
pubmed:affiliation
Novo Nordisk Research and Development, Novo Nordisk Park, DK 2760 Måløv, Denmark.
pubmed:publicationType
Journal Article